Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.
Gardner
Jennifer M
JM
Department of Dermatology, University of Pennsylvania, 3600 Spruce St, 2 Maloney Bldg, Philadelphia, PA 19104, USA. jennifer.gardner@uphs.upenn.edu
Evans
Katherine G
KG
Goldstein
Steven
S
Kim
Ellen J
EJ
Vittorio
Carmela C
CC
Rook
Alain H
AH
D000888:Antibodies, Anti-Idiotypic / Q000032:analysis / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D005500:Follow-Up Studies; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D007074:Immunoglobulin G / Q000276:immunology; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D010391:Pemphigoid, Bullous / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000077337:Vorinostat
D000888:Antibodies, Anti-Idiotypic; D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D007074:Immunoglobulin G; D000077337:Vorinostat